Download Publications List A / Prof Gavin Marx

Publications List
A / Prof Gavin Marx
As at : 16/04/2014
Hovey E, de Souza P, Marx G, Parente P, Rapke T, Hill A, Bonaventura A, Michele A, Craft P, Abdi E, Lloyd A; on behalf
of the MOTIF investigators. Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in
patients treated with docetaxel-based chemotherapy. Support Care Cancer. 2013 Dec 17.
Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P,
Morote J, Ye Z, Dansey R, Goessl C. Denosumab and bone metastasis-free survival in men with nonmetastatic castrationresistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013 Oct
20;31(30):3800
McLachlan JM, Marx GM, Bridgman M. Severe symptomatic hypocalcaemia following a single dose of denosumab. Med J
Aust. 2013 Aug 19;199(4):242-3.
von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL,
Palazzo FG, Qian Y, Braun A, Chung K.Pain and health-related quality of life in patients with advanced solid tumours and
bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support
Care Cancer. 2013 Dec;21(12):3497-507.
Won AC, Gurney H, Marx G, De Souza P, Patel MI. Primary treatment of the prostate improves local palliation in men who
ultimately develop castrate-resistant prostate cancer. BJU Int. 2013 Aug;112(4):E250-5.
Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., Marx, G., Cullen, M., Kerestes, Z., Pavlakis,
N. (2012), The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with
thalidomide alone or combined with cisplatin/gemcitabine. Lung cancer (Amsterdam, Netherlands). 75(2), 248-54. 2012
Kao, S. C.-H., Hovey, E. and Marx, G. Second-line therapy for castrate-resistant prostate cancer: A literature review. AsiaPacific Journal of Clinical Oncology, 7: 212–223. 2011
Tebbutt, N, Murphy, F, Zannino, D, Wilson, K, Cummins, M, Abdi, E, Strickland, A, Lowenthal, R, Marx, G, Karapetis, C,
Shannon, J, Goldstein, D, Nayagam, S, Blum, R, Chantrill, L, Simes, R, Price, T, Risk of arterial thromboembolic events in
patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology. 2011
Christos S Karapetis, Kerry A Cheong, Desmond Yip, Andrew H Strickland, Christopher Steer, Gavin Marx, Sonia
Yip, Kathryn Chrystal, Peter G Harper. A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and
sodium folinate in patients with advanced esophagogastric carcinomas. Asia-Pacific Journal of Clinical Oncology. Volume
6, Issue 4, pages 298–305, December 2010
Diana Adams and Gavin Marx. Daily Life As an Australian Medical Oncologist. Journal of Oncology Practice, Vol 6, No 3
(May), 2010: pp. 146-148.
C. B. Steer, G. M. Marx, N. Singhal, M. McJannett, D. Goldstein, R. Prowse. Cancer in older people: a tale of two
disciplines
Internal Medicine Journal. Volume 39, Issue 11, Date: November 2009, 39(11) Pages: 771-775
M. Khasraw1, N. Pavlakis1, S. McCowatt1,2, C. Underhill3, S. Begbie4, P. de Souza5, A. Boyce6, F. Parnis7, V. Lim1, R
Harvie1, and G Marx. Multicentre Phase I/II Study of PI-88, a Heparanase Inhibitor in Combination with Docetaxel in
Patients with Metastatic Castrate- Resistant Prostate Cancer. Annals of Oncology. Nov 2009
Liangli Zhao1, Brian Y. Lee1, David A. Brown3, Mark P. Molloy4, Gavin M. Marx5, Nick Pavlakis5, Michael J. Boyer6,
Martin R. Stockler6, Warren Kaplan2, Samuel N. Breit3, Robert L. Sutherland1, Susan M. Henshall1 and Lisa G. Horvath
Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. Cancer Research 69,
7696, October 1, 2009
Pavlakis N, Marx G, White S, Lee CW, Khasraw M. Anti-angiogenic therapy for lung cancer (Protocol). Cochrane Database
of Systematic Reviews 2009, Issue 4. Art. No.: CD008047. DOI: 10.1002/14651858.CD008047.
Elizabeth Hovey1, Gavin Marx2, Andrew Kneebone3, Manish Patel4 and Jeremy Shapiro An Australian Clinical Perspective:
Management of Hormone Refractory (Androgen-Independent) Prostate Cancer.Asia Pacific Journal of Oncology and
Haematology 2009
sah.org.au/find-a-specialist
Page 1 of 2
Publications List
A / Prof Gavin Marx
As at : 16/04/2014
Gavin M. Marx, Nick Pavlakis, Sally McCowatt, Stephen Begbie, Craig Underhill, Adam Boyce, David Bell, Phillip
Katelaris, Rozelle Harvie, Chris Ward. A Phase II Trial of Docetaxel and Thalidomide in Patients with Metastatic Androgen
Independent Prostate Cancer. The ProTaT Trial.
Manuscript in preparation.
Rozelle Harvie MSc 1,2, Florian Paturi 1, Robyn Taylor BAppSci 2, Ross Davey PhD1,2, Rick Abraham3, Gavin Marx2,
Martin Cullen2, Zoltan Kerestes PhD 1,2, and Nick Pavlakis1,2. The predictive role of serum VEGF in an advanced malignant
mesothelioma (MM) patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine . Manuscript in
preparation.
M. Khasraw and Gavin Marx. Chemotherapy in the elderly. Cancer Forum. Mar 2008. Vol 32 Issue1.
Gananadha, S., Hazebroek, E., Leibman, S., Berry, H., Osgood, L., Shon, I., Pavlakis, N., Marx, G., Smith, G. The utility of
FDG-PET in the preoperative staging of esophageal cancer. Diseases of the Esophagus. 2008; 21:389-394.
sah.org.au/find-a-specialist
Page 2 of 2